Skip to content

Efficacy of Psychological Therapy in Chronic Pain and Fibromyalgia

Efficacy of Mindfulness-based Pain Management in Patients With Chronic Pain With and Without Fibromyalgia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03992612
Acronym
DOLORTRATPSI
Enrollment
112
Registered
2019-06-20
Start date
2019-06-01
Completion date
2021-06-30
Last updated
2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Fibromyalgia

Keywords

Fibromyalgia, Chronic Pain, Psychological Treatment, Effectiveness, MBPM

Brief summary

Today, one of the most important challenges of the health system is the attitude towards chronic disorders. That implies changing from a health structure established for the treatment of acute diseases to a continued care system. In this sense, the approach of chronic pain, of non-oncological origin, supposes an important care challenge, to which this project wishes to respond. Chronic pain affects one of every Europeans (19%), and has a prevalence of 11% in Spain, being one of the most important causes of medical consultation and is associated with high personal, social and economic costs. For example, in 2017 it was calculated that it has an economic impact of between 1.7 and 2.1% of Spain's GDP. Referred to the psychological consequences of the disease, it has been found that 42% of people who have chronic pain suffer insomnia, a 40% anxiety, and 24% depressive symptoms. Hence the importance of implementing evidence-based psychological treatments along with their treatment as usual The main objective is comparing the efficacy of mindfulness-based pain management (MBPM), together with the usual medical treatment, in patients diagnosed with chronic pain, with and without comorbid fibromyalgia. Specific objectives are: 1. To study the sociodemographic and clinical profile of patients with chronic pain, with and without fibromyalgia. 2. Define the characteristics of patients who are in the different stages of the disease: stage 1 (less than two years since diagnosis); stage 2 (between 2 and 4 years); stage 3 (between 5 and 8 years), and stage 4 (more than 8 years). 3. Check the effectiveness of psychological therapies MBPM depending on the presence of fibromyalgia. 4. Check the effectiveness of the psychological treatment in function of the stage of the disease. Method: A quasi-experimental design of two groups will be used. Patients will be assigned to experimental group: 50 subjects will receive MBPM and control group 40 subjects, 3-months wait list, after which time they will also receive MBPM. All the participants will be assessed in the baseline; at the end of the treatment; and in the 1, 3, 6 and 12 months follow-ups. Group 2 (waiting list) will be assessed in the baseline, and re-assessed before starting the treatment; at the end of the psychological therapy; and in the 1, 3, 6 and 12 months follow-ups.

Detailed description

The objetive of this research are the study of efficacy in chronic pain and fybromyalgia of mindfulness therapy.

Interventions

OTHERcontrol group: usual medical care

The patients received usual medical care.

BEHAVIORALMBPM- Mindfulness-Based Pain Management

8 group session of maindfulness-based treatment to management pain

Sponsors

University of the Basque Country (UPV/EHU)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Be able to complete the assessment protocol * Suffer from chronic non-oncological pain, lasting longer than 6 months * Not being receiving psychological treatment * Sign the informed consent

Exclusion criteria

* Present a cognitive impairment, such as a dementia * Present a diagnosis of a psychotic disease, bipolar disease or additive disease

Design outcomes

Primary

MeasureTime frameDescription
Change in Lattinen Index- ILbase line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)It is a scale with five items to assess variables associated with pain: frequency, intensity, disability, drugs usage and sleep problems. These are assessed by a Likert scale of 0 to 4, in order to explain the discomfort that pain generates. (Gonzalez-Escada, 2012)

Secondary

MeasureTime frameDescription
Change in the Fibromyalgia Impact Questionnaire- FIQbase line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)its a 10 item scale that assesses the impact of the disease. The first item evaluates the interference of the disease in skills such as home care and work. The second item assesses how they felt last week; the third item values the days of last week that the disease prevented him from performing his usual tasks. Finally, the fourth item assesses the interference caused by pain and other items of the disease. It will only be completed by patients diagnosed with fibromyalgia. (Esteve et al., 2007)
Change in the Listado de Sintomas Breve- LSB-50base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)it is composed of 50 items, which are rated on a Likert scale from 0 to 4, depending on the level of discomfort caused by each item to the subject. it includes two scales of validity, three general indices, clinical scales (psychoreactivity, hypersensitivity, obsession, anxiety, hostility, somatization, depression, and sleep disturbances) and a psychological risk index. (de Rivera & Abuin, 2012)
Change in the Short Form 12 Health Survey- SF-12base line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)It assesses a patient's health perception in 12 areas like physical function, physical role, body pain, general health, vitality, social function, emotional role, and mental health. It is completed with Likert type response options from 3 to 5 points.(Schmidt et al., 2012)
Change in Cuestionario de afrontamiento del dolor- CAD-Rbase line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)It consists of 31 items related to the strategies that the patient performs when suffer pain. The strategies are valued from 1 (never use) to 5 (always use). The items are grouped into the following factors: religion, catharsis, distraction, information search, self-control, and self-affirmation. (Soriano & Monsaslve, 2002)
Change in Inventaire of negative thoughts in response to pain- INTRPbase line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)This questionnaire assesses the presence of negative thinking in response to pain. It consists of 21 items distributed in 5 factors: general negative thoughts, negative social thoughts, thoughts of disability, thoughts of lack of control, and thoughts of self-blame (Cano & Rodriguez, 2002)
Change Pain Catastrophizing Scale- PCSbase line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)The scale evaluates through 13 items the thoughts and feelings related to the experiences of pain. It is divided into three subscales, scored from 0 (never) to 4 (always), rumination, desperation, and magnification (Lami et al., 2013)
Change in Chronic Pain Acceptance Questionnaire- CPAQbase line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)The scale evaluates strategies of the pain experience. It consists of 20 items, scored from 0 (never true) to 6 (always true), from which three scores are obtained: involvement in activities, openness to pain, and total punctuation.
Change in Connor-Davison Resilience Scale- CDRISCbase line (week 0), end of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)The CD-RISC scale assesses resilience. Consist in 25 items and the subject has to indicate what extent each of the statements has been true, in his case, during the last month on a scale ranging from 0 (not true at all) to 4 (almost always true). Fernández-Lansac & Soberón, 2014)

Other

MeasureTime frameDescription
Client Satisfaction Questionnaireend of treatment (week 12); and during maintenance phase (weeks 17, 29 and 41)This scale assesses clients satisfaction with the treatment through 8 items, using a Likert scale from 0 to 4. (Larsen et al., 1978)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026